Gilead, Leo Pharma
Gilead roars into JPM25, inking $1.7B inflammation deal with Leo Pharma
Gilead continues its divergence out of its original infectious disease beginnings and into cancer and now, more deeply than before, into inflammation, penning a major $1.7 billion deal with dermatology specialist Leo Pharma on the eve of the J.P. Morgan Healthcare conference.
Harbor Capital Advisors Inc. grew its stake in Gilead Sciences, Inc. (NASDAQ:GILD – Free Report) by 2.3% during the 4th ...
Morgan Stanley has upgraded Gilead Sciences (NASDAQ:GILD) to overweight from equal weight, citing the company's HIV drug ...
Gilead Sciences, Inc. (GILD) and LEO Pharma entered strategic partnership to develop and commercialize LEO Pharma's small molecule ...
ST Germain D J Co. Inc. cut its holdings in Gilead Sciences, Inc. (NASDAQ:GILD – Free Report) by 15.9% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange ...
After the separation, Gilead will hold around 25% of the outstanding shares in both Galapagos and the spin-off company. While ...
Alongside plans to spin out a new company, the Belgian drugmaker said it will cut some 300 positions, or about 40% of its ...
The Marion Star on MSN8h
Cardington pulls away late in its rivalry game with Mount Gilead Saturday afternoonCardington overcomes Mount Gilead's second-half rally in a Knox Morrow Athletic Conference boys basketball game.
In a report released yesterday, Courtney Breen from Bernstein maintained a Buy rating on Gilead Sciences (GILD – Research Report), with a price ...
Gilead Sciences (GILD) ended the recent trading session at $89.14, demonstrating a -1.64% swing from the preceding day's closing price. The stock trailed the S&P 500, which registered a daily gain ...
The stock's rise snapped a five-day losing streak.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback